Social networks
447 3,588Activities
Technologies
Entity types
Location
10 Rue Grignan, 13001 Marseille, France
Marseille
France
Employees
Scale: 2-10
Estimated: 6
SIREN
534549209Engaged corporates
8Added in Motherbase
5 years, 6 months agoBiocellvia evaluates the efficacy of your lead molecules from histological slides thanks to our digital technology
Biocellvia is a french digital pathology company developing Intelligent Image Analysis solutions for pharmaceutical industry (Big Pharma, Biotechs, CRO) and academic communities involved in R&D.
We have developed digital image analysis solutions, that enable to evaluate fully-automatically the level of efficacy of your lead molecules thanks to histological slides (in vitro, ex vivo, biopsies) in various pathologies such as:
- Gastrointestinal (NASH, Liver fibrosis)
- Respiratory (IPF, COPD, PAH)
We provide image analysis as a service. Our technology evaluates your molecules with more accuracy, more reliability, more rapidity and less variability than traditional scoring methods. A full study (about 200 images) is performed in only a couple of days.
http://biocellvia.com
http://linkedin.com/company/biocellvia
Oncology, Quantification, Compound validation assays, Pulmonary fibrosis, COPD, Toxicology, Numerical imaging analysis, NASH , ASTHMA , CNS, Lung cancer, Histology, CRO, Contract Research Organization, Liver disease, Asthma, NAFLD, Respiratory disease, ex vivo, in vivo, in vitro, digital pathology, IPF, clinical trial, and preclinical
Biocellvia evaluates the efficacy of your lead molecules from histological slides thanks to our digital technology
Biocellvia is a french start-up developing intelligent image analysis solutions for pharmaceutical industry, chemistry, medical and academic communities involved in R&D.
Effectiveness and specificity are key points in our sector, that’s why Biocellvia has developed several innovative assays that evaluate, thanks to an independent observer, with a very high accuracy of the level of efficacy of active compounds for in vitro and ex vivo models in various pathologies such as:
- Gastrointestinal (NASH, Liver fibrosis)
- Respiratory (IPF, COPD, PAH)
Our strong scientific expertise (CSO Pr Yvon Julé) allows us to clearly understand you and therefore provide you with custom-tailored assays. Each laboratory has its own specificities, so with Biocellvia each client has his own solutions.
Innovation is our philosophy : all our assays are perfectly reliable, accurate, and also fully automated. With Biocellvia you can choose, our assays are available in your own laboratory by cloud solution, or you can entrust studies. Biocellvia saves your time and your money !
You need a very special assay? We're ready to take up the challenge !
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
SATT Sud-Est Research, National and local authorities, Research Services | SATT Sud-Est Research, National and local authorities, Research Services | Other 3 Feb 2024 | | |
Novo Nordisk Pharmaceutical, Pharmaceutical Manufacturing | Novo Nordisk Pharmaceutical, Pharmaceutical Manufacturing | Other 9 Feb 2024 | | |
thecamp Startup accelerator & VC, Business Consulting and Services | thecamp Startup accelerator & VC, Business Consulting and Services | Capitalistic Not partnership Not event 13 Mar 2019 | | |
Business France National and local authorities, Government Administration | Business France National and local authorities, Government Administration | Not capitalistic Partnership Event 18 Jun 2018 | | |
La French Tech Aix-Marseille Région Sud French Tech, Software Development | La French Tech Aix-Marseille Région Sud French Tech, Software Development | Other 8 Mar 2019 21 Nov 2023 | | |
Amgen Biotechnology, Biotechnology Research | Amgen Biotechnology, Biotechnology Research | Other 30 Nov 2021 | | |
AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | Other 9 Feb 2024 | | |
Roche Pharmaceutical, Biotechnology, Biotechnology Research | Roche Pharmaceutical, Biotechnology, Biotechnology Research | Other 30 Sep 2021 | |